Bionovo to Present Recent Findings of BN107, its Anticancer Agent, at the 31st Annual San Antonio Breast Cancer Symposium
Bionovo's poster presentation will describe the pathway for cancer cellapoptosis (cell death) induced by BN107. As explained by Dr. Emma Shtivelman,Director of Cancer Research at Bionovo, the ability of BN107 to induce cancercell death is distinct. BN107 induces apoptosis through the mitochondrialpathway. BN107 induces death only in estrogen receptor negative breast cancercells. Our studies show that cholesterol depletion and disruption of lipidraft-mediated signaling is most likely responsible for the pro-apoptoticeffect of BN107.
"BN107 mechanism of action and unique selective properties are a result ofsome of the biological differences exhibited uniquely by cancer cells. Webelieve BN107 will result in better selectivity to hormone independent tumors.Currently the only available treatment for this group, constituting 40% ofwomen diagnosed with breast cancer, is chemotherapy. BN107, an oral drugcandidate, should provide a chronic treatment option with a low toxicityprofile," said Dr. Isaac Cohen, Chairman and CEO of Bionovo
Bionovo is a pharmaceutical company focused on the discovery anddevelopment of safe and effective treatments for women's health and cancer,markets with significant unmet needs and billions in potential annual revenue.The company applies its expertise in the biology of menopause and cancer todesign new drugs derived from botanical sources which have novel mechanisms ofaction. Based on the results of early and mid-stage clinical trials, Bionovobelieves they have discovered new classes of drug candidates within their richpipeline with the potential to be leaders in their markets. Bionovo isheadquartered in Emeryville, California and is traded on the NASDAQ CapitalMarket under the symbol, "BNVI". For more information about Bionovo and itsprograms, visit: http://www.bionovo.com.
Forward Looking Statements
This release contains certain forward-looking statements relating to thebusiness of Bionovo, Inc. that can be identified by the use of forward-lookingterminology such as "believes," "expects," or similar expressions. Suchforward-looking statements involve known and unknown risks and uncertainties,including uncertainties relating to product development, efficacy and safety,regulatory actions or delays, the ability to obtain or maintain patent orother proprietary intellectual property protection, market acceptance,physician acceptance, third party reimbursement, future capital requirements,competition in general and other factors that may cause actual results to bematerially different from those described herein as anticipated, believed,estimated or expected. Certain of these risks and uncertainties are or will bedescribed in greater detail in our filings with the Securities and ExchangeCommission, which are available at http://www.sec.gov. Bionovo, Inc. is underno obligation (and expressly disclaims any such obligation) to update or alterits forward-looking statements whether as a result of new information, futureevents or otherwise.
SOURCE Bionovo, Inc.
You May Also Like